KRAS and colorectal carcinoma: More significantly, our cell cycle assay results display that the KRAS mutant CRC cells show an 8.6% (p < 0.005) greater increase in G2 phase cells, as well as 6.2% (p < 0.05) and 2.3% (p < 0.05) greater decreases in G1 and S phase cells, respectively, after 60 h of 10 μM PRMT5 inhibitor treatment when compared to the KRAS WT CRC cells (Figure 6).